IDEXX Laboratories, Inc. - Common Stock (IDXX)
460.56
-7.99 (-1.71%)
Idexx Laboratories is a global leader in veterinary diagnostics, providing a wide range of innovative products and services that enhance animal health and well-being
The company develops and manufactures diagnostic tests and equipment for companion animals, livestock, and poultry, helping veterinarians and livestock producers make informed health decisions. Additionally, Idexx offers various software solutions for practice management and laboratory information, along with water testing services to ensure public safety and environmental protection. With a commitment to advancing veterinary medicine and improving animal care, Idexx plays a crucial role in the healthcare ecosystem for animals and the people who care for them.
![](https://cdn.content.foolcdn.com/images/1umn9qeh/production/2c9ec3b6b9eb98b1cfd94a264f2d1785c57dffa5-600x400.jpg)
Idexx Laboratories exceeded earnings expectations for Q4 2024, buoyed by robust performance in its key diagnostic segments.
Via The Motley Fool · February 3, 2025
![](https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp)
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Monday.
Via Chartmill · February 3, 2025
![](https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp)
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top S&P500 gainers and losers in today's session.
Via Chartmill · February 3, 2025
![](https://www.investors.com/wp-content/uploads/2021/05/Stock-Idexx-02-adobe.jpg)
The company sells diagnostic equipment for veterinarians. Fourth-quarter metrics grew and beat expectations.
Via Investor's Business Daily · February 3, 2025
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_1.png?width=1200&height=800&fit=crop)
Via Benzinga · January 29, 2025
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_2.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · December 2, 2024
![](https://cdn.benzinga.com/files/images/story/2025/02/03/Wall-Street-subway-sign.jpeg?width=1200&height=800&fit=crop)
Wall Street bounced back after President Donald Trump and Mexican President Claudia Sheinbaum agreed to a one-month suspension of tariffs following Mexico's pledge to bolster its military presence at the northern borde
Via Benzinga · February 3, 2025
![](https://cdn.benzinga.com/files/images/story/2025/02/03/Stock-Movers.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · February 3, 2025
![](https://cdn.benzinga.com/files/images/story/2025/02/03/Pets-Cat-And-Dog-With-Big-Eyes-Ears-Poke.jpeg?width=1200&height=800&fit=crop)
Idexx Laboratories posted strong Q4 earnings, beating estimates with 10% EPS growth. 2025 guidance reflects up to 7% revenue growth and $1.5 billion in buybacks.
Via Benzinga · February 3, 2025
![](https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp)
Let's have a look at what is happening on the US markets on Monday. Below you can find the S&P500 stocks with an unusual volume in today's session.
Via Chartmill · January 27, 2025
![](https://cdn.benzinga.com/files/images/story/2025/01/26/Chatbot-Conversation-Ai-Artificial-Intel.jpeg?width=1200&height=800&fit=crop)
Katy Huberty, the Global Head of Research at Morgan Stanley, has spotlighted 20 stocks from companies that are likely to see significant benefits from the adoption of Artificial Intelligence (AI).
Via Benzinga · January 26, 2025
![](https://cdn.benzinga.com/files/images/story/2025/01/21/Jim-Cramer-Photo-by-s-bukley-on-Shutters.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 21, 2025
![](https://cdn.benzinga.com/files/images/story/2024/12/22/Healthcare--Opioid-Epidemic-And-Drug-Abu.jpeg?width=1200&height=800&fit=crop)
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb.
Via Benzinga · December 22, 2024
![](https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 4, 2024
![](https://g.foolcdn.com/editorial/images/799957/gettyimages-1725491683.jpg)
Via The Motley Fool · December 13, 2024
![](https://g.foolcdn.com/editorial/images/796649/buy-sell-metal-dice-470277287.jpg)
Is it a good time to scoop up last month's biggest losers? Check out October's largest price drops on the Nasdaq, and see whether any of them look like good buys today.
Via The Motley Fool · November 6, 2024
![](https://g.foolcdn.com/editorial/images/795979/gettyimages-530977027-5.jpg)
Trading at its most reasonable valuation since 2016, this pet healthcare diagnostics leader could be a once-in-a-decade opportunity today.
Via The Motley Fool · November 5, 2024
![](https://cdn.benzinga.com/files/images/story/2024/10/31/Vet-Dog-Pet.jpeg?width=1200&height=800&fit=crop)
Idexx Laboratories posted a Q3 EPS of $2.79, beating estimates, though revenue of $975.54 million fell short. Veterinary trends and guidance update key 2024 outlook.
Via Benzinga · October 31, 2024
![](https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · October 10, 2024